×
About 17,353 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  6,066 results

CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute l...
https://doi.org/10.1002/pbc.29323
Pediatric Blood & Cancer; Mejstrikova E, Klinger M et. al.

Sep 15th, 2021 - Blinatumomab is a BiTE® (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset of patien...

Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric A...
https://doi.org/10.1182/bloodadvances.2021004716
Blood Advances; Johnsrud AJ, Craig J et. al.

Sep 15th, 2021 - Bleeding and thrombotic events are an emerging toxicity associated with chimeric antigen receptor (CAR) therapies. To determine their incidence, we retrospectively analyzed consecutive adult patients (n=127) with large B-cell lymphoma (LBCL) or B-...

SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity i...
https://doi.org/10.1016/j.clml.2021.07.009
Clinical Lymphoma, Myeloma & Leukemia; Schmiegelow K, Rank CU et. al.

Sep 14th, 2021 - A wider use of L-asparaginase in the treatment of children with acute lymphoblastic leukemia has improved cure rates during recent decades and hence led to introduction of pediatric-inspired treatment protocols for adolescents and young adults. In...

Dasatinib-based Two-step Induction for Adults with Philadelphia Chromosome-Positive Acu...
https://doi.org/10.1182/bloodadvances.2021004607
Blood Advances; Sugiura I, Doki N et. al.

Sep 14th, 2021 - The standard treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, approximately 40%...

Relapsed acute lymphoblastic leukemia.
https://doi.org/10.1016/j.ajo.2021.08.020
American Journal of Ophthalmology; Chen JL, Vatanatham CC et. al.

Sep 13th, 2021 - Relapsed acute lymphoblastic leukemia.|2021|Chen JL,Vatanatham CC,Tsui E,|

see more →

Guidelines  3 results

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  110 results see all →

Clinicaltrials.gov  15 results

EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language
https://clinicaltrials.gov/ct2/show/NCT05040230

Sep 10th, 2021 - The investigators will conduct a prospective cohort study of all patients who received CAR T cell infusions in the hematology department from Montpellier University Medical Center. To be eligible for enrollment, patients should have to be 18 years...

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
https://clinicaltrials.gov/ct2/show/NCT05026229

Sep 8th, 2021 - About 25% of adult patients with acute lymphoblastic leukemia (ALL) are associated with t (9; 22), positive philadelphia chromosome (Ph+ ALL), in whom BCR/ABL fusion gene can be detected in the bone marrow and peripheral blood. The use of tyrosine...

Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)
https://clinicaltrials.gov/ct2/show/NCT04322084

Sep 8th, 2021 - Primary Objectives (Feasibility Phase) To determine the feasibility of non-invasive collection of continuous physiological data in children with acute lymphoblastic leukemia during outpatient treatment. (Completion Phase) To develop competing seps...

Venetoclax Plus Inotuzumab for B-ALL
https://clinicaltrials.gov/ct2/show/NCT05016947

Sep 2nd, 2021 - This is a phase I study of venetoclax in combination with inotuzumab ozogamicin for the treatment of CD22-positive (CD22+) B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma (B-LBL), hereafter referred to as "ALL," in patients with disease r...

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05032183

Sep 2nd, 2021 - PRIMARY OBJECTIVE: I. To evaluate the overall response rate (complete response [CR] + CR with inadequate count recovery [CRi]) of the regimen within 3 cycles. SECONDARY OBJECTIVES: I. Evaluate other clinical efficacy endpoints (CR rate, minimal re...

see more →

News  747 results

Choosing a Treatment Setting for Patients With ALL
https://www.onclive.com/view/choosing-a-treatment-setting-for-patients-with-all

Aug 18th, 2021 - Ibrahim Aldoss, MD: Which patients with Philadelphia chromosome-positive [Ph+] acute lymphoblastic leukemia may be safely treated in the community setting versus being referred to tertiary centers? Let’s extend that also to Philadelphia chromosome...

Approaches to Treatment of Ph- ALL
https://www.onclive.com/view/approaches-to-treatment-of-ph--all

Aug 18th, 2021 - Ibrahim Aldoss, MD: Are your treatment goals different based on age and Ph-negative ALL [acute lymphoblastic leukemia]? And typically, if we're still talking about AYA (adolescent and young adult) versus older adults, or even with the AYA, there's...

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL
https://www.onclive.com/view/mrd-as-a-prognostic-indicator-in-children-and-young-adults-with-very-high-risk-all

Aug 11th, 2021 - Data from the following presentations are discussed: Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leu...

GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL
https://www.onclive.com/view/gimema-lall2317-sequential-chemotherapy-and-blinatumomab-for-adult-all

Aug 11th, 2021 - Data from the following presentations are discussed: Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab front-line trial for newly diagnosed adult Ph-negative B-lineage ALL patients. (Bassan, EHA 2021 S114) Efficacy: ...

Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL
https://www.onclive.com/view/phase-ii-results-ponatinib-blinatumomab-in-ph-all

Aug 11th, 2021 - Data from the following presentations are discussed: Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. (Short, ASCO 2021 Abstract 7001) Efficacy: 28 p...

see more →